Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-01-13

Clinical Trial Update: Evaluate the Neurological Effects of EryDex on Subjects With A-T [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the neurological effects of EryDex in people with Ataxia Telangiectasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EryDex

Snippet

Sponsor: Quince Therapeutics S.p.A. | Conditions: Ataxia Telangiectasia | Phase 3 | Status: COMPLETED